To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Laboratory | Genomics | Cancer
Carl MANN, Researcher
Carl.Mann@Cea.FrJean-Yves THURET, Researcher
Senescence can be triggered in conditions associated with genomic instability such as the loss of telomeric sequences when somatic human cells undergo excessive proliferation with insufficient telomerase expression. Senescence can also be triggered by the expression of hyper-mitogenic oncogenes. The development of a tumor requires the expression of oncogenes that provoke uncontrolled proliferation. Remarkably however, the expression of oncogenes such as RASval12 or B-RAF-V600E can trigger senescence when expressed in normal human cells. Thus, for a tumor to develop, senescence effector pathways involving the tumor suppressors p53 and Rb must be inactivated. How can oncogene expression trigger senescence? The production of reactive oxygen species and DNA damage associated with replicative stress have been implicated in senescence induced by RASval12 expression. However, we found that RAF-induced senescence can occur without apparent oxidative stress, DNA damage or DNA replication (Jeanblanc et al. Oncogene. 2012). We are thus interested in defining novel pathways contributing to RAF-induced senescence. The B-RAF-V600E oncogenic mutation is a major driver mutation in melanoma and also contributes significantly to several other human cancers including thyroid and colorectal carcinomas. We have produced a model human fibroblast cell line in which we can modulate the expression of B-RAF-V600E to study the pathways leading to RAF-induced senescence. Hypothesis-based and systems biology approaches are being used to identify pathways. The importance of these pathways will be confirmed using a mouse model in which conditional expression of B-RAF-V600E leads to melanocyte senescence.
senescence of mammalian cells is characterized by a proliferative arrest in
response to stress and the expression of an inflammatory phenotype. Chromatin
modifications have been implicated in the stable repression of proliferative
genes in senescence, and in the derepression of inflammatory genes. We used
mass spectrometry to characterize the chromatin of senescent cells. We discovered that H2A.J, a poorly studied H2A variant found
only in mammals, accumulates in human fibroblasts in senescence with persistent
DNA damage. H2A.J also accumulates in mice with aging in a tissue-specific
manner. Knock-down of H2A.J inhibited the derepression of inflammatory genes
that contribute to the senescent-associated secretory phenotype (SASP), and
over-expression of H2A.J increased the expression of some of these genes in
proliferating cells. H2A.J accumulation may thus promote the signaling of
senescent cells to the immune system, and it may contribute to chronic
inflammation and the development of diseases with aging. We are currently
investigating the mechanism by which H2A.J promotes inflammatory gene
expression in senescent cells, and we are interested in studying its functions
in tissues in which H2A.J accumulation does not appear to be linked to
The accumulation of senescent cells has been implicated in various human pathologies associated with stress or aging. Senescence may interfere with tissue regeneration by limiting the proliferation of stem cells, and the secretion of inflammatory factors by senescent cells may have negative paracrine effects associated with chronic inflammation. Mouse models have indicated that the genetic elimination of senescent cells may limit some phenotypes associated with aging. We are screening for small molecules/natural products that modulate the senescent phenotype in collaboration with the Chemistry department and the PARi screening platform at the CEA/Saclay. Molecules that bypass or revert senescence, that inhibit the inflammatory phenotype, or that are specifically toxic for senescent cells are all of interest (figure 3). These molecules may serve as probes to dissect senescence mechanisms, and they may represent lead compounds for modulating senescence in human diseases. A pilot screen of the Prestwick chemical library composed of FDA-approved drugs revealed a profound effect of a specific class of compounds on RAF-induced senescence. We are currently performing transcriptome analyses to determine how these molecules modulate senescence.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.